tbuckley/cabot-search huggingface dataset:
Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study.
Authors: Celestia S. Higano, Shawn H. Zimberg, Sabina Dizdarevic, Lauren Christine Harshman, John Logue, Sergio Baldari, Timothy Richardson, David M. Bottomley, Martin Schostak, Bertrand F. Tombal, Juan Pablo Sade, Kurt Miller, Christopher Logothetis, Joaquim Bellmunt, Matthew Raymond Smith, Fred Saad, Renate Muenz-Wollny, Yoriko De Sanctis, A. Oliver Sartor, Cora N. Sternberg
Journal: Journal of Clinical Oncology (2017)

5042 Background: Ra-223, a targeted alpha therapy, prolonged survival with good safety in metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 ALSYMPCA trial. REASSURE will evaluate Ra-223 short- and long-term safety in routine clinical practice settings. This is the first planned interim analysis (median 7 mo observation). Methods: This global, prospective, single-arm, observational study enrolled pts with mCRPC with bone metastases (mets) for whom Ra-223 therapy was planned. Follow-up will continue up to 7 years after last Ra-223 dose. Results: 1106 pts (437 N. America, 665 Europe, 4 not recorded) enrolled from 2 Sep 2014 to 22 Sep 2016. Baseline data are available from 583 pts receiving 1st- (1L), 2nd- (2L), or ≥3rd-line (≥3L) Ra-223 for mCRPC(Table). The majority of pts (n=369, 63%) completed 5–6 doses (1L, 70%; 2L, 64%; ≥3L, 49%); median 6 doses (1L,6; 2L, 6; ≥3L, 4). Treatment-emergent drug-related AEs occurred in 215 pts (37%). Post-treatment grade 3/4 thrombocytopenia occurred in 14 pts (2.4%) and anemia in 45 (7.7%). Conclusions: In routine clinical practice, Ra-223 was associated with no short-term safety concerns and appeared to be used in pts with less advanced mCRPC than in ALSYMPCA. The majority of pts on 1L/2L Ra-223 therapy received 5–6 doses. Ra-223 was often used with abiraterone or enzalutamide, but not chemotherapy. The next interim analysis in 2019 will report long-term safety and outcomes on all pts. Clinical trial information: NCT02141438. [Table: see text]
Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial
Authors: J. Strosberg, E.M. Wolin, B. Chasen, M.H. Kulke, D. Bushnell, M. Caplin, R.P. Baum, P. Kunz, T. Hobday, A. Hendifar, K. Öberg, M. Lopera Sierra, P. Ruszniewski, E. Krenning
Journal: Annals of Oncology (2017)
KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer
Authors: Z.A. Wainberg, S. Jalal, K. Muro, H.H. Yoon, M. Garrido, T. Golan, T. Doi, D.V. Catenacci, R. Geva, G. Ku, J. Bleeker, Y-J. Bang, H. Hara, H.C. Chung, M. Savage, J. Wang, M. Koshiji, R. Dalal, C.S. Fuchs
Journal: Annals of Oncology (2017)
A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1)
Authors: M.R. Mirza, J. Wang, M. Mau-Sørensen, M.J. Birrer, X. Wang, M. Jørgensen, Z-Y. Zhang, H. Roed, S. Malander, F. Nielsen, L. Bjørge, U. Lassen, L. Boufercha, K. Brøsen, V. Kansra, J. Mäenpää
Journal: Annals of Oncology (2017)
mTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion
Authors: William J. Quinn, Min Wan, Swapnil V. Shewale, Rebecca Gelfer, Daniel J. Rader, Morris J. Birnbaum, Paul M. Titchenell
Journal: Journal of Clinical Investigation (2017)

Liver triacylglycerol (TAG) synthesis and secretion are closely linked to nutrient availability. After a meal, hepatic TAG formation from fatty acids is decreased, largely due to a reduction in circulating free fatty acids (FFA). Despite the postprandial decrease in FFA-driven esterification and oxidation, VLDL-TAG secretion is maintained to support peripheral lipid delivery and metabolism. The regulatory mechanisms underlying the postprandial control of VLDL-TAG secretion remain unclear. Here, we demonstrated that the mTOR complex 1 (mTORC1) is essential for this sustained VLDL-TAG secretion and lipid homeostasis. In murine models, the absence of hepatic mTORC1 reduced circulating TAG, despite hepatosteatosis, while activation of mTORC1 depleted liver TAG stores. Additionally, mTORC1 promoted TAG secretion by regulating phosphocholine cytidylyltransferase α (CCTα), the rate-limiting enzyme involved in the synthesis of phosphatidylcholine (PC). Increasing PC synthesis in mice lacking mTORC1 rescued hepatosteatosis and restored TAG secretion. These data identify mTORC1 as a major regulator of phospholipid biosynthesis and subsequent VLDL-TAG secretion, leading to increased postprandial TAG secretion.
Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.
Authors: Lydia Gaba, Iván Victoria, Estela Pineda, Aranzazu Fernandez, Francisco Aya, Aleix Prat, Ana M Arance
Journal: Journal of Clinical Oncology (2015)

9069 Background: The anti-PD1 antibody (Ab) Nivolumab (Nivo) has demonstrated to improve the overall survival (OS) in patients (pts) with metastatic melanoma (MM) compared to DTIC. Pembrolizumab (Pembro), another anti-PD1, showed durable antitumor activity in pts with MM and has been approved in the US for the treatment (tmt) of MM that progressed on ipilimumab and, if BRAFV600 mutant, a BRAF inhibitor. To date, no lab test has been identified to predict clinical benefit (CB) to anti-PD1 Abs. Methods: This retrospective observational study included pts with MM who received anti-PD1 tmt in a single institution. The objective was to identify whether an increase of at least 100/mm3 at 3 weeks over the baseline or increase > 400/mm3 at 12 weeks in the absolute eosinophil counts (AEC) could predict CB. Blood tests were performed before every administration. Response to tmt according immune-related response criteria, progression free survival (PFS) and OS were evaluated. Descriptive statistics were used to analyze patient baseline characteristics. Response rates (RR) were compared by exact Fisher test. PFS and OS were estimated by the Kaplan-Meier method. Results: From March 2013 to December 2014, 29 pts were treated with anti-PD1 Abs (3 pts with Nivo and 26 pts with Pembro). Median age was 57 years (range 30-83) with 10.3% stage M1a, 24.1% M1b and 65.5% M1c, and 51.7% had elevated LDH. Pts who experienced an increase in AEC over the baseline > 100/mm3 at 3 weeks demonstrated better outcomes in terms of RR (55.6% vs 9.1%, p = 0.190), PFS (9.9 [95% CI: 5.8-14.0] vs 2.6 [95% CI: 1.0-4.2] months, p = 0.008) and OS (18.8 [95% CI: 15.5-22.1] vs 6.9 [95% CI: 3.5-10.3] months, p = 0.001) compared with those who did not. Moreover, pts with an AEC > 400/mm3 at 12 weeks responded to tmt (100% vs 18.2%, p = 0.002) and showed more benefit regarding PFS (18.6 vs 3.6 months, p < 0.0001) and OS (not reached vs 11.4 months, p = 0.017) compared to those who did not. Conclusions: An increase in AEC of 100/mm3 over baseline at week 3 and an absolute AEC > 400/mm3 at week 12 during anti-PD1 tmt might identify pts with MM most likely to experience long-term disease control with anti-PD1 Abs.
Ampliando horizontes, abriendo puertas
Authors: S Handysides
Journal: Eurosurveillance (1999)

Esta edicion de Eurosurveillance incluye un articulo cuya publicacion requiere una explicacion. El asma no es una enfermedad infecciosa en si, pero se sabe que ciertas infecciones viricas precipitan las crisis de asma y las personas con esta enfermedad son mas propensas a padecer ataques prolongados de ‘bronquitis aguda', cuyo manejo clinico puede diferir de la atencion de la bronquitis aguda en personas sin asma. La Organizacion Mundial de la Salud estima que, en todo el mundo, hay 150 millones de personas afectadas por asma, hecho que convierte a esta enfermedad en un importante problema de salud publica en terminos de calidad de vida, perdidas de dias de trabajo o de educacion, costos farmaceuticos e incluso mortalidad.
Individualized Pazopanib Dosing—Letter
Authors: Audrey Bellesoeur, Pascaline Boudou-Rouquette, Audrey Thomas-Schoemann, Charlotte Joly, Camille Tlemsani, Michel Vidal, François Goldwasser, Benoit Blanchet
Journal: Clinical Cancer Research (2017)

Following the articles by Verheijen and colleagues and Mir and colleagues reporting individualized pazopanib dosing strategy ([1, 2][1]), we wish to share our experience on pazopanib dose monitoring. From January 2014 to June 2017, we monitored trough pazopanib concentration ( C min) in plasma from
Delayed Repolarization Underlies Ventricular Arrhythmias in Rats With Heart Failure and Preserved Ejection Fraction
Authors: Jae Hyung Cho, Rui Zhang, Peter J. Kilfoil, Romain Gallet, Geoffrey de Couto, Catherine Bresee, Joshua I. Goldhaber, Eduardo Marbán, Eugenio Cingolani
Journal: Circulation (2017)

Heart failure with preserved ejection fraction (HFpEF) represents approximately half of heart failure, and its incidence continues to increase. The leading cause of mortality in HFpEF is sudden death, but little is known about the underlying mechanisms.Dahl salt-sensitive rats were fed a high-salt diet (8% NaCl) from 7 weeks of age to induce HFpEF (n=38). Rats fed a normal-salt diet (0.3% NaCl) served as controls (n=13). Echocardiograms were performed to assess systolic and diastolic function from 14 weeks of age. HFpEF-verified and control rats underwent programmed electrical stimulation. Corrected QT interval was measured by surface ECG. The mechanisms of ventricular arrhythmias (VA) were probed by optical mapping, whole-cell patch clamp to measure action potential duration and ionic currents, and quantitative polymerase chain reaction and Western blotting to investigate changes in ion channel expression.After 7 weeks of a high-salt diet, 31 of 38 rats showed diastolic dysfunction and preserved ejection fraction along with signs of heart failure and hence were diagnosed with HFpEF. Programmed electric stimulation demonstrated increased susceptibility to VA in HFpEF rats (P<0.001 versus controls). The arrhythmogenicity index was increased (P<0.001) and the corrected QT interval on ECG was prolonged (P<0.001) in HFpEF rats. Optical mapping of HFpEF hearts demonstrated prolonged action potentials (P<0.05) and multiple reentry circuits during induced VA. Single-cell recordings of cardiomyocytes isolated from HFpEF rats confirmed a delay of repolarization (P=0.001) and revealed downregulation of transient outward potassium current (Ito; P<0.05). The rapid components of the delayed rectifier potassium current (IKr) and the inward rectifier potassium current (IK1) were also downregulated (P<0.05), but the current densities were much lower than for Ito. In accordance with the reduction of Ito, both Kcnd3 transcript and Kv4.3 protein levels were decreased in HFpEF rat hearts.Susceptibility to VA was markedly increased in rats with HFpEF. Underlying abnormalities include QT prolongation, delayed repolarization from downregulation of potassium currents, and multiple reentry circuits during VA. Our findings are consistent with the hypothesis that potassium current downregulation leads to abnormal repolarization in HFpEF, which in turn predisposes to VA and sudden cardiac death.
Paracrine factors produced by bone marrow stromal cells induce apoptosis in LNCaP and C4-2B prostate cancer cells
Authors: Chu Zhang, Daniel Carson, Mary Farach-Carson
Journal: Cancer Research (2007)

2780   Preferential metastasis of human prostate cancer cells to bone marrow contributes to disease mortality and morbidity. Local factors present in the bone stromal extracellular matrix microenvironment affect tumor growth through paracrine interactions between tumor and stromal cells. We studied the interactions between prostate cancer and bone stromal cells using three prostate cancer cell lines: PC3, LNCaP, and the LNCaP derivative subline, C4-2B. Co-culture of LNCaP and C4-2B cells with the bone marrow stromal cell lines, HS27a and HS5, decreased cell number, as did culture with conditioned medium (CM) harvested from these two bone stromal cell lines suggesting a soluble paracrine factor was responsible. PC3 cell growth was not affected. Interestingly, CM harvested from bone stromal cell lines triggered apoptosis in LNCaP and C4-2B cell lines, but not in PC3 cells. Surviving prostate cancer cells grown in bone stromal cell CM over several days were growth arrested, suggesting the presence of a growth inhibitor. Apoptosis induced by CM was dose dependent. Flow cytometry demonstrated that over a five day culture period in stromal cell CM, LNCaP and C4-2B cell lines, but not PC3, underwent considerably more apoptosis compared to parallel cultures grown in serum free medium. The LNCaP and C42B cells also showed morphology changes after exposure to stromal cell CM. These results suggest that the bone stromal microenvironment is initially hostile to prostate cancer cells resulting in cancer cell apoptosis. Activation of survival pathways in a subset of apoptotic resistant cells may support phenotypic adaptation during disease progression in bone, eventually favoring the osteoblastic transformation characteristic of prostate cancer. Supported by NIH/ NCI (P01 CA098912) and DOD (W81XWH-04-1-0919).
Optimal therapy of hepatitis C
Authors: Adrian M. Di Bisceglie, Jay H. Hoofnagle
Journal: Hepatology (2002)

The highest response rates to antiviral therapy for the treatment of chronic hepatitis C have been achieved using the combination of peginterferon and ribavirin. Recently completed controlled trials have reported rates of sustained virological response (SVR) between 50% and 60% in patients treated with higher doses of peginterferon and ribavirin, which was 5% to 10% higher with standard doses of interferon alfa and ribavirin. The major determinant of outcome of therapy is hepatitis C virus (HCV) genotype. With the combination of peginterferon and ribavirin, patients with genotype 1 achieve response rates of 40% to 45%, compared with rates approaching 80% with genotypes 2 or 3 . Importantly, patients with HCV genotype 1 achieve higher rates of response with 48 weeks than with 24 weeks of therapy, whereas patients with genotypes 2 and 3 are adequately treated with a 24-week course. Furthermore, patients with genotypes 2 and 3 require only 800 mg of ribavirin daily to achieve optimal response rates, whereas 1,000 to 1,200 mg daily is needed for patients with genotype 1 . Future studies should focus on optimizing the dose of peginterferon and ribavirin by patient characteristics, particularly on resolving the issue of weight-based dosing. For patients with good prognostic factors, a lower dose and shorter course of peginterferon may be adequate for full effect. Importantly, research is needed to show how treatment regimens can best be applied to other patient groups with hepatitis C, such as patients with acute hepatitis, human immunodeficiency virus coinfection, renal disease, solid-organ transplant, neuropyschiatric disease, autoimmunity, and alcohol or substance abuse.
From hepatitis C virus infection to B-cell lymphoma
Authors: L. Couronné, E. Bachy, S. Roulland, B. Nadel, F. Davi, M. Armand, D. Canioni, J.M. Michot, C. Visco, L. Arcaini, C. Besson, O. Hermine
Journal: Annals of Oncology (2017)
Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
Authors: P. Nuciforo, A. Prat, A. Llombart, R. Fasani, L. Paré, T. Pascual, M. Oliveira, N. Martínez Jañez, B. Bermejo De Las Heras, M. Vidal, S. Pernas Simon, R. López, M. Muñoz, I. Garau, L. Manso, J. Alarcon Company, E. Martinez de Dueñas, P. Villagrasa Gonzalez, J. Cortes Castan, E. Holgado
Journal: Annals of Oncology (2017)
Paediatric radiation therapy across Europe: A European questionnaire survey supported by the SIOPe, ESTRO, PROS and several national paediatric hematology-oncology societies (NAPHOS)
Authors: C. Demoor-Goldschmidt, C. Carrie, G. Whitfield, P. Meijinders, K. Dieckmann, B. Timmermann, L. Zaletel, P. Banovic, M. Solak Mekic, Y. Lassen, K. Alexopoulou, J. Giralt, J. Vizkeleti, L. Jarusevicius, B. Ondrova, P. Daly, P. Brandal, G. Janssens, U. Ricardi, R. Dieter-Kortmann
Journal: Annals of Oncology (2017)
Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial
Authors: C. Cardone, M.C. Paul, V. Moreno-Viedma, G. Martini, P.P. Vitiello, D. Ciardiello, V. Sforza, T. Troiani, S. Napolitano, P. Vitale, N. Zanaletti, A.M. Rachiglio, D. Rizzi, E. Maiello, N. Normanno, M. Sibilia, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2017)
Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20)
Authors: N. Masuda, S. Ohtani, T. Takano, K. Inoue, E. Suzuki, R. Nakamura, H. Bando, Y. Ito, K. Ishida, T. Yamanaka, K. Kuroi, H. Yasojima, H. Kasai, T. Takasuka, T. Sakurai, T.R. Kataoka, S. Morita, S. Ohno, M. Toi
Journal: Annals of Oncology (2017)
How to write a Critically Appraised Topic: evidence to underpin routine clinical practice
Authors: J. Callander, A.V. Anstey, J.R. Ingram, J. Limpens, C. Flohr, P.I. Spuls
Journal: British Journal of Dermatology (2017)

Critically appraised topics (CATs) are essential tools for busy clinicians who wish to ensure that their daily clinical practice is underpinned by evidence-based medicine. CATs are short summaries of the most up-to-date, high-quality available evidence that is found using thorough structured methods. They can be used to answer specific, patient-orientated questions that arise recurrently in real-life practice. This article provides readers with a detailed guide to performing their own CATs. It is split into four main sections reflecting the four main steps involved in performing a CAT: formulation of a focused question, a search for the most relevant and highest-quality evidence, critical appraisal of the evidence and application of the results back to the patient scenario. As well as helping to improve patient care on an individual basis by answering specific clinical questions that arise, CATs can help spread and share knowledge with colleagues on an international level through publication in the evidence-based dermatology section of the British Journal of Dermatology.
Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions
Authors: Won Young Tak, Shi-Ming Lin, Yijun Wang, Jiasheng Zheng, Aldo Vecchione, Soo Young Park, Min Hua Chen, Stephen Wong, Ruocai Xu, Cheng-Yuan Peng, Yi-You Chiou, Guan-Tarn Huang, Jianqiang Cai, Basri Johan Jeet Abdullah, June Sung Lee, Jae Young Lee, Jong-Young Choi, Julieta Gopez-Cervantes, Morris Sherman, Richard S. Finn, Masao Omata, Michael O'Neal, Lukas Makris, Nicholas Borys, Ronnie Poon, Riccardo Lencioni
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Lyso-thermosensitive liposomal doxorubicin (LTLD) consists of doxorubicin contained within a heat-sensitive liposome. When heated to ≥40°C, LTLD locally releases a high concentration of doxorubicin. We aimed to determine whether adding LTLD improves the efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) lesions with a maximum diameter (dmax) of 3 to 7 cm. Experimental Design: The HEAT Study was a randomized, double-blind, dummy-controlled trial of RFA ± LTLD. The 701 enrolled patients had to have ≤4 unresectable HCC lesions, at least one of which had a dmax of 3 to 7 cm. The primary endpoint was progression-free survival (PFS) and a key secondary endpoint was overall survival (OS). Post hoc subset analyses investigated whether RFA duration was associated with efficacy. Results: The primary endpoint was not met; in intention-to-treat analysis, the PFS HR of RFA + LTLD versus RFA alone was 0.96 [95% confidence interval (CI), 0.79-1.18; P = 0.71], and the OS HR ratio was 0.95 (95% CI, 0.76–1.20; P = 0.67). Among 285 patients with a solitary HCC lesion who received ≥45 minutes RFA dwell time, the OS HR was 0.63 (95% CI, 0.41–0.96; P &amp;lt; 0.05) in favor of combination therapy. RFA + LTLD had reversible myelosuppression similar to free doxorubicin. Conclusions: Adding LTLD to RFA was safe but did not increase PFS or OS in the overall study population. However, consistent with LTLD's heat-based mechanism of action, subgroup analysis suggested that RFA + LTLD efficacy is improved when RFA dwell time for a solitary lesion ≥45 minutes. Clin Cancer Res; 24(1); 73–83. ©2017 AACR.
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells
Authors: Francesca Megiorni, Giovanni Luca Gravina, Simona Camero, Simona Ceccarelli, Andrea Del Fattore, Vincenzo Desiderio, Federica Papaccio, Heather P. McDowell, Rajeev Shukla, Antonio Pizzuti, Filip Beirinckx, Philippe Pujuguet, Laurent Saniere, Ellen Van der Aar, Roberto Maggio, Francesca De Felice, Cinzia Marchese, Carlo Dominici, Vincenzo Tombolini, Claudio Festuccia, Francesco Marampon
Journal: Journal of Hematology & Oncology (2017)

EPH (erythropoietin-producing hepatocellular) receptors are clinically relevant targets in several malignancies. This report describes the effects of GLPG1790, a new potent pan-EPH inhibitor, in human embryonal rhabdomyosarcoma (ERMS) cell lines. EPH-A2 and Ephrin-A1 mRNA expression was quantified by real-time PCR in 14 ERMS tumour samples and in normal skeletal muscle (NSM). GLPG1790 effects were tested in RD and TE671 cell lines, two in vitro models of ERMS, by performing flow cytometry analysis, Western blotting and immunofluorescence experiments. RNA interfering experiments were performed to assess the role of specific EPH receptors. Radiations were delivered using an x-6 MV photon linear accelerator. GLPG1790 (30 mg/kg) in vivo activity alone or in combination with irradiation (2 Gy) was determined in murine xenografts. Our study showed, for the first time, a significant upregulation of EPH-A2 receptor and Ephrin-A1 ligand in ERMS primary biopsies in comparison to NSM. GLPG1790 in vitro induced G1-growth arrest as demonstrated by Rb, Cyclin A and Cyclin B1 decrease, as well as by p21 and p27 increment. GLPG1790 reduced migratory capacity and clonogenic potential of ERMS cells, prevented rhabdosphere formation and downregulated CD133, CXCR4 and Nanog stem cell markers. Drug treatment committed ERMS cells towards skeletal muscle differentiation by inducing a myogenic-like phenotype and increasing MYOD1, Myogenin and MyHC levels. Furthermore, GLPG1790 significantly radiosensitized ERMS cells by impairing the DNA double-strand break repair pathway. Silencing of both EPH-A2 and EPH-B2, two receptors preferentially targeted by GLPG1790, closely matched the effects of the EPH pharmacological inhibition. GLPG1790 and radiation combined treatments reduced tumour mass by 83% in mouse TE671 xenografts. Taken together, our data suggest that altered EPH signalling plays a key role in ERMS development and that its pharmacological inhibition might represent a potential therapeutic strategy to impair stemness and to rescue myogenic program in ERMS cells.
GW28-e1071 Clinical Utility of Real-time Three-Dimensional Echocardiography in the Evaluation of Lead-Induced Tricuspid Regurgitation
Authors: Qing Li, Ruijie Li, Lulu Zhao, Xuejuan Ma, Ruizhi Ni, Yun Gu, Ling Zhao
Journal: Journal of the American College of Cardiology (2017)